AAM Strengthens Calls For Reforms To Stop Anticompetitive Tactics
Six Areas Listed Including Skinny Label Carve Outs
Executive Summary
The US Association for Accessible Medicines discussed six areas for reform during a recent US Senate Judiciary Committee hearing “shining a spotlight on the anti-competitive tactics used by some brand name pharmaceutical companies to delay patient access” to generics and biosimilars.